[go: up one dir, main page]

DK3472207T3 - BINDING MOLECULES THAT BIND PD-L1 AND LAYER-3 - Google Patents

BINDING MOLECULES THAT BIND PD-L1 AND LAYER-3 Download PDF

Info

Publication number
DK3472207T3
DK3472207T3 DK17752291.9T DK17752291T DK3472207T3 DK 3472207 T3 DK3472207 T3 DK 3472207T3 DK 17752291 T DK17752291 T DK 17752291T DK 3472207 T3 DK3472207 T3 DK 3472207T3
Authority
DK
Denmark
Prior art keywords
bind
layer
binding molecules
molecules
binding
Prior art date
Application number
DK17752291.9T
Other languages
Danish (da)
Inventor
Jamie Campbell
Nikole Sandy
Mihriban Tuna
Van Horck Francisca Wollerton
Katy Louise Everett
Miguel Gaspar
Matthew Kraman
Katarzyna Kmiecik
Mustapha Faroudi
Natalie Fosh
Barbara Hebeis
Original Assignee
F Star Delta Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Star Delta Ltd filed Critical F Star Delta Ltd
Application granted granted Critical
Publication of DK3472207T3 publication Critical patent/DK3472207T3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4201—Neoantigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/50—Colon
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C07K2318/20—Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DK17752291.9T 2016-06-20 2017-06-20 BINDING MOLECULES THAT BIND PD-L1 AND LAYER-3 DK3472207T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662352482P 2016-06-20 2016-06-20
PCT/EP2017/065073 WO2017220569A1 (en) 2016-06-20 2017-06-20 Binding molecules binding pd-l1 and lag-3

Publications (1)

Publication Number Publication Date
DK3472207T3 true DK3472207T3 (en) 2021-04-12

Family

ID=59631719

Family Applications (1)

Application Number Title Priority Date Filing Date
DK17752291.9T DK3472207T3 (en) 2016-06-20 2017-06-20 BINDING MOLECULES THAT BIND PD-L1 AND LAYER-3

Country Status (25)

Country Link
US (2) US11214620B2 (en)
EP (2) EP3858858A1 (en)
JP (2) JP7085709B2 (en)
KR (2) KR20190019144A (en)
CN (1) CN109563171B (en)
AR (1) AR110101A1 (en)
AU (1) AU2017283181B2 (en)
BR (1) BR112018076519A8 (en)
CA (1) CA3027612A1 (en)
CY (1) CY1124232T1 (en)
DK (1) DK3472207T3 (en)
ES (1) ES2858091T3 (en)
HR (1) HRP20210602T1 (en)
HU (1) HUE053742T2 (en)
IL (1) IL263730B2 (en)
LT (1) LT3472207T (en)
MX (1) MX2018016320A (en)
PL (1) PL3472207T3 (en)
PT (1) PT3472207T (en)
RS (1) RS61705B1 (en)
SG (1) SG11201811064TA (en)
SI (1) SI3472207T1 (en)
SM (1) SMT202100213T1 (en)
TW (1) TW201803906A (en)
WO (1) WO2017220569A1 (en)

Families Citing this family (101)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
US10519237B2 (en) 2014-03-12 2019-12-31 Yeda Research And Development Co. Ltd Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
BR112016020919A2 (en) 2014-03-12 2018-01-23 Yeda Res & Dev reduced levels or systemic activity of regulatory t cells for the treatment of snc disease and injury
US10618963B2 (en) 2014-03-12 2020-04-14 Yeda Research And Development Co. Ltd Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
TWI756187B (en) 2015-10-09 2022-03-01 美商再生元醫藥公司 Anti-lag3 antibodies and uses thereof
WO2017136820A2 (en) 2016-02-06 2017-08-10 Epimab Biotherapeutics, Inc. Fabs-in-tandem immunoglobulin and uses thereof
SG11201810509PA (en) 2016-06-20 2018-12-28 Kymab Ltd Anti-pd-l1 antibodies
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
DK3472207T3 (en) * 2016-06-20 2021-04-12 F Star Delta Ltd BINDING MOLECULES THAT BIND PD-L1 AND LAYER-3
CA3027302A1 (en) * 2016-06-20 2017-12-28 F-Star Beta Limited Binding members(1)
GB201612520D0 (en) 2016-07-19 2016-08-31 F-Star Beta Ltd Binding molecules
US11779604B2 (en) 2016-11-03 2023-10-10 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses and methods
MA47456A (en) 2017-02-10 2019-12-18 Regeneron Pharma RADIO-LABELED ANTI-LAG3 ANTIBODIES FOR IMMUNO-PET IMAGING
MX2019012038A (en) 2017-05-30 2019-11-18 Bristol Myers Squibb Co Compositions comprising a combination of an anti-lag-3 antibody, a pd-1 pathway inhibitor, and an immunotherapeutic agent.
IL322104A (en) 2017-05-30 2025-09-01 Bristol Myers Squibb Co Treatment of tumors that express LAG–3
AU2018275209A1 (en) 2017-05-30 2019-10-17 Bristol-Myers Squibb Company Compositions comprising an anti-LAG-3 antibody or an anti-LAG-3 antibody and an anti-PD-1 or anti-PD-L1 antibody
WO2019121906A1 (en) * 2017-12-19 2019-06-27 F-Star Beta Limited Specific pd-l1 binding sequences inserted in a ch3 domain
CN109970856B (en) 2017-12-27 2022-08-23 信达生物制药(苏州)有限公司 anti-LAG-3 antibodies and uses thereof
WO2019129054A1 (en) * 2017-12-27 2019-07-04 信达生物制药(苏州)有限公司 Triabody, preparation method and use thereof
WO2019165982A1 (en) * 2018-02-28 2019-09-06 WuXi Biologics Ireland Limited Monoclonal antibody against human lag-3, method for preparing same, and use thereof
CN110343178B (en) * 2018-04-03 2022-07-22 上海开拓者生物医药有限公司 Anti-human LAG-3 monoclonal antibody and application thereof
CA3097916A1 (en) * 2018-05-03 2019-11-07 Shanghai Epimab Biotherapeutics Co., Ltd. High affinity antibodies to pd-1 and lag-3 and bispecific binding proteins made therefrom
CA3100712A1 (en) * 2018-05-17 2019-11-21 Immunome, Inc. Ch3 domain epitope tags
WO2019246142A1 (en) * 2018-06-18 2019-12-26 Haiming Chen Soluble bispecific fusion proteins for cancer immunotherapy
GB201811450D0 (en) 2018-07-12 2018-08-29 F Star Delta Ltd Mesothelin and CD137 binding molecules
GB201811415D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd Anti-Mesothelin Anti bodies
GB201811410D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd OX40 Binding molecules
GB201811404D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd Anti-CD137 Antibodies
IL280002B2 (en) 2018-07-12 2025-05-01 F Star Beta Ltd Antibody molecules that bind cd137 and ox40
WO2020011964A1 (en) 2018-07-12 2020-01-16 F-Star Beta Limited Antibody molecules that bind pd-l1 and cd137
GB201811408D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd CD137 Binding Molecules
GB201811403D0 (en) * 2018-07-12 2018-08-29 F Star Beta Ltd Antibody molecules
EP4667493A2 (en) 2018-07-26 2025-12-24 Bristol-Myers Squibb Company Lag-3 combination therapy for the treatment of cancer
PT4445958T (en) 2018-10-19 2025-11-26 Bristol Myers Squibb Co Combination therapy for melanoma
CA3103525A1 (en) * 2018-12-17 2020-06-25 Illumina, Inc. Flow cells and sequencing kits
TWI756621B (en) * 2019-01-25 2022-03-01 大陸商信達生物製藥（蘇州）有限公司 Novel bispecific antibody molecules and bispecific antibodies that simultaneously bind pd-l1 and lag-3
EP3715375A1 (en) 2019-03-23 2020-09-30 Ablevia biotech GmbH Compound for the prevention or treatment of pre-eclampsia
US11986536B2 (en) 2019-03-23 2024-05-21 Ablevia Biotech Gmbh Compound for the sequestration of undesirable antibodies in a patient
EP3715376A1 (en) 2019-03-23 2020-09-30 Ablevia biotech GmbH Compound for the prevention or treatment of myasthenia gravis
EP3715374A1 (en) 2019-03-23 2020-09-30 Ablevia biotech GmbH Compound for the sequestration of undesirable antibodies in a patient
EP3725370A1 (en) 2019-04-19 2020-10-21 ImmunoBrain Checkpoint, Inc. Modified anti-pd-l1 antibodies and methods and uses for treating a neurodegenerative disease
SG11202112136RA (en) * 2019-05-14 2021-11-29 F Star Therapeutics Ltd Dosage regimes for the administration of a lag-3/pd-l1 bispecific antibody
EP3976832A1 (en) 2019-05-30 2022-04-06 Bristol-Myers Squibb Company Methods of identifying a subject suitable for an immuno-oncology (i-o) therapy
JP2022534967A (en) 2019-05-30 2022-08-04 ブリストル－マイヤーズ スクイブ カンパニー Multiple tumor gene signatures and their uses
KR20220016157A (en) 2019-05-30 2022-02-08 브리스톨-마이어스 스큅 컴퍼니 Cell localization signatures and combination therapies
WO2021024020A1 (en) 2019-08-06 2021-02-11 Astellas Pharma Inc. Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer
CN114450028A (en) 2019-09-22 2022-05-06 百时美施贵宝公司 Quantitative spatial profiling for LAG-3antagonist therapy
EP4034569A4 (en) * 2019-09-26 2023-11-01 Wuxi Biologics Ireland Limited A novel anti-pd-l1/anti-lag-3 bispecific antibody and uses thereof
WO2021092220A1 (en) 2019-11-06 2021-05-14 Bristol-Myers Squibb Company Methods of identifying a subject with a tumor suitable for a checkpoint inhibitor therapy
WO2021092221A1 (en) 2019-11-06 2021-05-14 Bristol-Myers Squibb Company Methods of identifying a subject with a tumor suitable for a checkpoint inhibitor therapy
JP2022553851A (en) 2019-11-08 2022-12-26 ブリストル－マイヤーズ スクイブ カンパニー LAG-3 antagonists for the treatment of melanoma
CN110950966B (en) * 2019-12-13 2020-12-11 启辰生生物科技(珠海)有限公司 Fusion protein, encoding nucleic acid and cell and application
IL294207A (en) * 2019-12-23 2022-08-01 Macrogenics Inc Cancer treatment
JP2023509516A (en) 2020-01-07 2023-03-08 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム Improved human methylthioadenosine/adenosine-depleting enzyme variants for cancer therapy
US20230112470A1 (en) 2020-01-29 2023-04-13 Board Of Regents, The University Of Texas System Use of egfr/her2 tyrosine kinase inhibitors and/or her2/her3 antibodies for the treatment of cancers with nrg1 fusions
CA3166295A1 (en) 2020-01-29 2021-08-05 John Heymach Use of poziotinib for the treatment of cancers with nrg1 fusions
JP2023514152A (en) 2020-02-06 2023-04-05 ブリストル－マイヤーズ スクイブ カンパニー IL-10 and its uses
US20220363762A1 (en) * 2020-05-12 2022-11-17 Astrazeneca Ab Methods and combinations for the treatment of cancer using immune checkpoint inhibitor antibodies
US20250262293A1 (en) 2020-07-07 2025-08-21 BioNTech SE Therapeutic rna for hpv-positive cancer
AU2021331476A1 (en) 2020-08-28 2023-05-04 Bristol-Myers Squibb Company Lag-3 antagonist therapy for hepatocellular carcinoma
US20230303700A1 (en) 2020-08-31 2023-09-28 Bristol-Myers Squibb Company Cell localization signature and immunotherapy
EP4216990A1 (en) 2020-09-23 2023-08-02 Ablevia biotech GmbH Compound for the sequestration of undesirable antibodies in a patient
MX2023004493A (en) 2020-10-23 2023-05-10 Bristol Myers Squibb Co Lag-3 antagonist therapy for lung cancer.
WO2022120179A1 (en) 2020-12-03 2022-06-09 Bristol-Myers Squibb Company Multi-tumor gene signatures and uses thereof
CN115819585B (en) * 2020-12-10 2023-06-02 北京东方百泰生物科技股份有限公司 anti-LAG-3 monoclonal antibody, antigen binding fragment thereof and application thereof
WO2022135666A1 (en) 2020-12-21 2022-06-30 BioNTech SE Treatment schedule for cytokine proteins
TW202245808A (en) 2020-12-21 2022-12-01 德商拜恩迪克公司 Therapeutic rna for treating cancer
WO2022135667A1 (en) 2020-12-21 2022-06-30 BioNTech SE Therapeutic rna for treating cancer
MX2023007734A (en) 2020-12-28 2023-08-21 Bristol Myers Squibb Co Antibody compositions and methods of use thereof.
MX2023007650A (en) 2020-12-28 2023-09-11 Bristol Myers Squibb Co Subcutaneous administration of pd1/pd-l1 antibodies.
WO2022165214A1 (en) 2021-01-29 2022-08-04 Board Of Regents, The University Of Texas System Methods of treating cancer with kinase inhibitors
WO2022212400A1 (en) 2021-03-29 2022-10-06 Juno Therapeutics, Inc. Methods for dosing and treatment with a combination of a checkpoint inhibitor therapy and a car t cell therapy
EP4319755A4 (en) 2021-04-08 2025-03-26 Board of Regents, The University of Texas System Compounds and methods for theranostic targeting of PARP activity
US20240285740A1 (en) 2021-05-12 2024-08-29 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating cancer
CA3225254A1 (en) 2021-07-13 2023-01-19 BioNTech SE Multispecific binding agents against cd40 and cd137 in combination therapy for cancer
TW202333802A (en) 2021-10-11 2023-09-01 德商拜恩迪克公司 Therapeutic rna for lung cancer
AU2022375806A1 (en) 2021-10-29 2023-12-14 Bristol-Myers Squibb Company Lag-3 antagonist therapy for hematological cancer
JP2025503962A (en) 2022-01-26 2025-02-06 ブリストル－マイヤーズ スクイブ カンパニー Combination Therapy for Hepatocellular Carcinoma
AU2023226078A1 (en) 2022-02-25 2024-08-22 Bristol-Myers Squibb Company Combination therapy for colorectal carcinoma.
WO2023168404A1 (en) 2022-03-04 2023-09-07 Bristol-Myers Squibb Company Methods of treating a tumor
JP2025508076A (en) 2022-03-08 2025-03-21 アレンティス・セラピューティクス・アクチェンゲゼルシャフト Use of anti-claudin-1 antibodies to improve T cell availability
WO2023170633A1 (en) * 2022-03-10 2023-09-14 Mendus B.V. Use of modified cells of leukemic origin and pd-l1 antibody for enhancing the efficacy of cancer cell therapy
WO2023178329A1 (en) 2022-03-18 2023-09-21 Bristol-Myers Squibb Company Methods of isolating polypeptides
CA3258064A1 (en) 2022-06-02 2023-12-07 Bristol-Myers Squibb Company Antibody compositions and methods of use thereof
WO2024107731A2 (en) * 2022-11-14 2024-05-23 Ablexis, Llc Anti-pd-l1 antibodies
CN120390652A (en) 2022-12-01 2025-07-29 免疫医疗有限公司 Combination therapy comprising an anti-PD-L1 antibody and an anti-CD73 antibody for treating cancer
IL321098A (en) 2022-12-14 2025-07-01 Astellas Pharma Europe Bv Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and immune checkpoint inhibitors
KR20250123912A (en) 2022-12-21 2025-08-18 브리스톨-마이어스 스큅 컴퍼니 Combination therapy for lung cancer
EP4665410A1 (en) 2023-02-17 2025-12-24 Regeneron Pharmaceuticals, Inc. Radiolabeled anti-lag3 antibodies for immuno-pet imaging
WO2024196952A1 (en) 2023-03-20 2024-09-26 Bristol-Myers Squibb Company Tumor subtype assessment for cancer therapy
GB202304278D0 (en) 2023-03-23 2023-05-10 F Star Therapeutics Ltd Dosage regimens for the administration of a bispecific antibody in combination with chemotherapy
WO2025038763A1 (en) 2023-08-15 2025-02-20 Bristol-Myers Squibb Company Ceramic hydroxyapatite chromatography flow through method
TW202535926A (en) 2023-10-30 2025-09-16 美商再生元醫藥公司 Stable antibody formulation
WO2025120867A1 (en) 2023-12-08 2025-06-12 Astellas Pharma Inc. Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and anti-vegfr2 antibodies
TW202541837A (en) 2023-12-08 2025-11-01 日商安斯泰來製藥公司 Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2
WO2025120866A1 (en) 2023-12-08 2025-06-12 Astellas Pharma Inc. Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2
WO2025145207A1 (en) 2023-12-29 2025-07-03 Bristol-Myers Squibb Company Combination therapy of kras inhibitor and treg-depleting agent
WO2025184208A1 (en) 2024-02-27 2025-09-04 Bristol-Myers Squibb Company Anti-ceacam5 antibodies and uses thereof
US12521446B2 (en) 2024-02-27 2026-01-13 Bristol-Myers Squibb Company Anti-CEACAM5 antibody drug conjugates
WO2025226695A1 (en) 2024-04-23 2025-10-30 Regeneron Pharmaceuticals, Inc. Stable antibody formulation
WO2025245489A1 (en) 2024-05-24 2025-11-27 Bristol-Myers Squibb Company Treatment of tumors in subjects having fgl-1 positive samples

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2245404C3 (en) 1972-09-15 1978-08-31 Robert Bosch Gmbh, 7000 Stuttgart Ground resistance, especially for spark plugs, and methods of manufacturing the same
JPS531908B2 (en) 1973-11-12 1978-01-23
JPS5746634B2 (en) 1974-05-10 1982-10-04
JPS5146628A (en) 1974-10-17 1976-04-21 Nippon Denso Co TEIKOIRISUPAAKUPURAGU
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS61134325A (en) 1984-12-04 1986-06-21 Teijin Ltd Expression of hybrid antibody gene
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
DE19818214A1 (en) 1998-04-24 1999-10-28 Bosch Gmbh Robert Spark plug for combustion engine
JP4578025B2 (en) 2001-07-06 2010-11-10 日本特殊陶業株式会社 Spark plug
AU2006204459B2 (en) 2005-01-05 2012-11-01 F-Star Therapeutics Limited Synthetic immunoglobulin domains with binding properties engineered in regions of the molecule different from the complementarity determining regions
CN104356236B (en) * 2005-07-01 2020-07-03 E.R.施贵宝&圣斯有限责任公司 Human monoclonal antibody against programmed death ligand 1 (PD-L1)
ES2975748T3 (en) 2007-06-26 2024-07-12 F Star Therapeutics Ltd Presentation of bonding agents
EP2113255A1 (en) 2008-05-02 2009-11-04 f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. Cytotoxic immunoglobulin
AR072999A1 (en) 2008-08-11 2010-10-06 Medarex Inc HUMAN ANTIBODIES THAT JOIN GEN 3 OF LYMPHOCYTARY ACTIVATION (LAG-3) AND THE USES OF THESE
EP2407487A1 (en) 2010-07-14 2012-01-18 F-Star Biotechnologische Forschungs - und Entwicklungsges. M.B.H. Multispecific modular antibody
EP2546268A1 (en) 2011-07-13 2013-01-16 F-Star Biotechnologische Forschungs - und Entwicklungsges. M.B.H. Internalising immunoglobulin
UY34887A (en) 2012-07-02 2013-12-31 Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware OPTIMIZATION OF ANTIBODIES THAT FIX THE LYMPHOCYTE ACTIVATION GEN 3 (LAG-3) AND ITS USES
JP5276742B1 (en) 2012-08-09 2013-08-28 日本特殊陶業株式会社 Spark plug
ES2808654T3 (en) 2013-03-15 2021-03-01 Glaxosmithkline Ip Dev Ltd Anti-LAG-3 binding proteins
WO2015048312A1 (en) * 2013-09-26 2015-04-02 Costim Pharmaceuticals Inc. Methods for treating hematologic cancers
LT3116909T (en) * 2014-03-14 2020-02-10 Novartis Ag ANTI-BODY MOLECULES AGAINST LAG-3 AND THEIR USE
JP5902757B2 (en) 2014-06-24 2016-04-13 日本特殊陶業株式会社 Spark plug
WO2015198312A1 (en) 2014-06-24 2015-12-30 Ccam Therapeutics Ltd. Compositions comprising antibodies to ceacam-1 and lag-3 for cancer therapy
TWI693232B (en) 2014-06-26 2020-05-11 美商宏觀基因股份有限公司 Covalently bonded diabodies having immunoreactivity with pd-1 and lag-3, and methods of use thereof
EP3178139A1 (en) 2014-08-10 2017-06-14 Federal-Mogul Ignition Company Spark plug with improved seal
JO3663B1 (en) 2014-08-19 2020-08-27 Merck Sharp & Dohme Anti-lag3 antibodies and antigen-binding fragments
MX2017014083A (en) 2015-05-04 2018-11-09 Pieris Pharmaceuticals Gmbh Anti-cancer fusion polypeptide.
MX2017014699A (en) 2015-05-21 2018-04-11 Alligator Bioscience Ab Novel polypeptides.
TWI773646B (en) 2015-06-08 2022-08-11 美商宏觀基因股份有限公司 Lag-3-binding molecules and methods of use thereof
JP6025921B1 (en) 2015-06-22 2016-11-16 日本特殊陶業株式会社 Spark plug
KR20180029238A (en) 2015-07-15 2018-03-20 피어이스 파마슈티컬즈 게엠베하 A novel protein specific for LAG-3
AR105444A1 (en) 2015-07-22 2017-10-04 Sorrento Therapeutics Inc THERAPEUTIC ANTIBODIES THAT JOIN THE PROTEIN CODIFIED BY THE GENOPHYPE ACTIVATION GEN 3 (LAG3)
KR20180035906A (en) 2015-08-07 2018-04-06 피어이스 파마슈티컬즈 게엠베하 New fusion polypeptides specific for LAG-3 and PD-1
KR101782487B1 (en) 2015-09-24 2017-09-27 재단법인 목암생명과학연구소 Novel Antibody Binding to Mesothelin(MSLN), and Composition Comprising the Same
TWI756187B (en) 2015-10-09 2022-03-01 美商再生元醫藥公司 Anti-lag3 antibodies and uses thereof
GB201519481D0 (en) 2015-11-04 2015-12-16 Cancer Rec Tech Ltd Immunomodulatory antibodies
UA121914C2 (en) 2015-11-18 2020-08-10 Мерк Шарп І Доум Корп. Pd1 and/or lag3 binders
US20190330336A1 (en) 2015-11-19 2019-10-31 Sutro Biopharma, Inc. Anti-lag3 antibodies, compositions comprising anti-lag3 antibodies and methods of making and using anti-lag3 antibodies
JP7022993B2 (en) 2016-01-11 2022-02-21 インヒブルクス インコーポレイテッド Multivalued and multispecific 41BB binding fusion protein
RU2018139339A (en) 2016-04-22 2020-05-22 Эллигейтор Биосайенс Аб NEW SPECIFIC POLYPEPTIDES AGAINST CD137
DK3472207T3 (en) 2016-06-20 2021-04-12 F Star Delta Ltd BINDING MOLECULES THAT BIND PD-L1 AND LAYER-3
CA3027302A1 (en) 2016-06-20 2017-12-28 F-Star Beta Limited Binding members(1)
US9567399B1 (en) * 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
SG11201810509PA (en) 2016-06-20 2018-12-28 Kymab Ltd Anti-pd-l1 antibodies
GB201612520D0 (en) 2016-07-19 2016-08-31 F-Star Beta Ltd Binding molecules
US11746152B2 (en) 2016-07-20 2023-09-05 Stcube, Inc. Methods of cancer treatment and therapy using a combination of antibodies that bind glycosylated PD-L1
EA201990578A1 (en) 2016-09-23 2019-10-31 BINDING MOLECULES THAT MODULATE THE CELL BIOLOGICAL ACTIVITY
GB201700345D0 (en) 2017-01-09 2017-02-22 F-Star Beta Ltd Conditional agonists of immune responses
CA3071211A1 (en) 2017-08-04 2019-02-07 Genmab A/S Binding agents binding to pd-l1 and cd137 and use thereof
WO2019121906A1 (en) 2017-12-19 2019-06-27 F-Star Beta Limited Specific pd-l1 binding sequences inserted in a ch3 domain
GB201811404D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd Anti-CD137 Antibodies

Also Published As

Publication number Publication date
LT3472207T (en) 2021-05-10
US20190256602A1 (en) 2019-08-22
SI3472207T1 (en) 2021-04-30
IL263730B2 (en) 2024-06-01
JP2019526273A (en) 2019-09-19
JP2022095746A (en) 2022-06-28
KR20190019144A (en) 2019-02-26
SMT202100213T1 (en) 2021-05-07
AU2017283181A1 (en) 2019-01-03
MX2018016320A (en) 2019-05-30
PL3472207T3 (en) 2021-07-12
IL263730B1 (en) 2024-02-01
KR102664891B1 (en) 2024-05-13
HUE053742T2 (en) 2021-07-28
RU2018143241A3 (en) 2020-11-11
KR20230035680A (en) 2023-03-14
SG11201811064TA (en) 2019-01-30
TW201803906A (en) 2018-02-01
US20220185894A1 (en) 2022-06-16
RU2018143241A (en) 2020-07-21
WO2017220569A1 (en) 2017-12-28
BR112018076519A8 (en) 2022-07-12
BR112018076519A2 (en) 2019-04-02
EP3472207B1 (en) 2021-01-20
JP7085709B2 (en) 2022-06-17
ES2858091T3 (en) 2021-09-29
US11214620B2 (en) 2022-01-04
PT3472207T (en) 2021-03-31
CN109563171A (en) 2019-04-02
AU2017283181B2 (en) 2024-08-15
CY1124232T1 (en) 2022-05-27
EP3472207A1 (en) 2019-04-24
JP7464644B2 (en) 2024-04-09
CN109563171B (en) 2023-09-19
EP3858858A1 (en) 2021-08-04
IL263730A (en) 2019-01-31
RS61705B1 (en) 2021-05-31
CA3027612A1 (en) 2017-12-28
HRP20210602T1 (en) 2021-05-14
AR110101A1 (en) 2019-02-27

Similar Documents

Publication Publication Date Title
DK3472207T3 (en) BINDING MOLECULES THAT BIND PD-L1 AND LAYER-3
DK3820569T3 (en) ANTIBODY MOLECULES THAT BINDING PD-L1 AND CD137
DK3370768T3 (en) ANTIBODIES THAT SPECIFICALLY BIND PD-1 AND USES THEREOF
IL272159A (en) Binding agents associated with PD-L1 and CD137 and use thereof
HUE055207T2 (en) PD-1 and LAG-3 binding molecules and methods for their use
DK3476399T3 (en) LAG-3 ANTIBODY, ANTIGIN BINDING FRAGMENT AND PHARMACEUTICAL APPLICATION
DK3328888T5 (en) ANTI-PSMA antibodies, bispecific antigen binding molecules that bind PSMA AND and CD3, and uses thereof
IL263715A (en) Lag -3 binding members
EP3652212A4 (en) LAG-3 BINDING ANTIBODIES AND USES THEREOF
DK3328889T3 (en) BISPECIFIC ANTIBODY CONSTRUCTIONS BINDING DLL3 AND CD3
DK3328892T3 (en) BISPECIFIC ANTIBODY CONSTRUCTIONS BINDING EGFRVIII AND CD3
DK3223845T3 (en) HETERODIMERING ANTIBODIES BINDING CD3 AND CD20
DK3097122T3 (en) ANTIBODIES BINDING BETA-KLOTHO DOMAIN 2 AND METHODS OF USING IT
DK3998285T3 (en) BINDING MOLECULES FOR CD38 AND PD-L1
DK3265575T3 (en) CD20 BINDING MOLECULES AND USES THEREOF
DK3665198T3 (en) ANTIBODIES THAT BINDING EGFR AND CMET
DK3122781T3 (en) BISPECIFIC ANTIBODIES BINDING TO CD38 AND CD3
DK3317301T3 (en) COMBINATION THERAPIES INCLUDING ANTIBODY MOLECULES AGAINST LAYER-3
DK3275899T3 (en) OPTIMIZATION OF ANTIBODIES BINDING LYMPHOCATE ACTIVATION GENE-3 (LAYER-3) AND USES THEREOF
DK3303379T3 (en) TIGIT BINDING MATERIALS AND USES THEREOF
DK3592384T3 (en) ANTIBODIES THAT SPECIFICALLY BINDING TO HUMAN IL-1R7
DK3200822T3 (en) BINDING MOLECULES, IN PARTICULAR ANTIBODIES THAT BIND TO L1CAM (CD171)
SG11202004904XA (en) Binding molecules that specifically bind to tau
DK3725803T3 (en) Binding molecules that bind human complement factor C2b, and uses thereof
GB201702091D0 (en) Specific binding molecules